Novo Nordisk is perhaps best known for mainstream obesity and diabetes medicines. However, the company is also committed to expanding into new disease areas where there are significant unmet patient needs. A growing circle of HCPs will administer those medicines, yet access to providers is declining, and time is of the essence in reaching patients. <\/p>\n
Frank Armenante, Novo Nordisk\u2019s field systems director, is considering the best ways to find and engage HCPs and believes it\u2019ll require new alignment between sales, marketing, market access, and medical teams. He sees a direct route to the goal by providing commercial teams with shared data and technology. <\/p>\n
\u201cAs we enter new disease states, the customers are changing, and the software has to keep up. The technology is now here, so we made the change,\u201d he says of the decision to be an early adopter of ³Ô¹Ï±¬ÁÏ Vault CRM<\/a>.<\/p>\n Taking calculated and educated risks moves the business and industry forward in a compliant way, according to Armenante. \u201cTechnology changes, disease states change, our industry changes, and we learn. Things change rapidly, and it\u2019s not like it was even three years ago. It’s a nice intersection where we\u2019re going and where the technology to align commercial teams is today.\u201d<\/p>\n